吡格列酮使用与头颈癌之间的关联：基于人群的病例对照研究。
Association between pioglitazone use and head and neck cancer: Population-based case-control study.
作者信息
Yang Tzong-Hann, Xirasagar Sudha, Cheng Yen-Fu, Wu Chuan-Song, Kao Yi-Wei, Shia Ben-Chang, Lin Herng-Ching
机构信息
Department of Otorhinolaryngology, Taipei City Hospital, Taipei, Taiwan.
Department of Speech, Language and Audiology, National Taipei University of Nursing and Health, Taipei, Taiwan.
出版信息
Head Neck. 2020 Apr;42(4):653-659. doi: 10.1002/hed.26046. Epub 2019 Dec 13.
BACKGROUND
This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer.
METHODS
Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis.
RESULTS
Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P < .001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95% CI: 1.02-1.10) among cases relative to controls.
CONCLUSIONS
Prior pioglitazone use was associated with oral cavity cancer.
背景
本研究旨在评估使用吡格列酮与头颈癌发生之间的关联。
方法
本病例对照研究的数据取自台湾国民健康保险研究数据库。共识别出21464例新诊断出头颈癌的糖尿病患者。我们使用倾向评分匹配法选择了64392例对照患者（比例为3:1）。采用多因素logistic回归模型来检验在癌症诊断前5年使用吡格列酮与头颈癌之间的关联。
结果
双变量分析显示，病例组和对照组之前使用吡格列酮的患病率存在显著差异（19.3%对18.5%，P＜0.001）。多因素回归分析显示，病例组相对于对照组使用吡格列酮的校正比值比为1.06（95%置信区间：1.02 - 1.10）。
结论
之前使用吡格列酮与口腔癌有关。
Zotero 插件